Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

Published:2014-02-21 Issue:4 Volume:13 Page:842-854
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Knutson Sarah K.,Kawano Satoshi,Minoshima Yukinori,Warholic Natalie M.,Huang Kuan-Chun,Xiao Yonghong,Kadowaki Tadashi,Uesugi Mai,Kuznetsov Galina,Kumar Namita,Wigle Tim J.,Klaus Christine R.,Allain Christina J.,Raimondi Alejandra,Waters Nigel J.,Smith Jesse J.,Porter-Scott Margaret,Chesworth Richard,Moyer Mikel P.,Copeland Robert A.,Richon Victoria M.,Uenaka Toshimitsu,Pollock Roy M.,Kuntz Kevin W.,Yokoi Akira,Keilhack Heike

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 461 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study;International Journal of Hematology;2024-08-23

2. Dual-target EZH2 inhibitor: latest advances in medicinal chemistry;Future Medicinal Chemistry;2024-07-31

3. CRISPR activation screens identify the SWI/SNF ATPases as suppressors of ferroptosis;Cell Reports;2024-06

4. EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2;Cancer Science;2024-04-16

5. Disruption of G-quadruplex dynamicity by BRCA2 abrogation instigates phase separation and break-induced replication at telomeres;Nucleic Acids Research;2024-04-08